Glaucoma News and Research

Latest Glaucoma News and Research

Liu Laboratory at Augusta University studies exosomes using Particle Metrix’s ZetaView

Particle Metrix, developers of versatile particle characterization solutions for the life sciences, report on the work in the Liu Laboratory at Augusta University which is studying exosomes where size and concentration are critical parameters.

4 Apr 2016

New technologies go far beyond traditional use of contact lenses for vision correction

Imagine contact lenses that can deliver medicines directly to the eye, slow progression of nearsightedness in children, or monitor glucose levels in patients with diabetes.

1 Apr 2016

IUPUI investigators use stem cells to identify potential therapies to prevent glaucoma

Using stem cells derived from human skin cells, researchers led by Jason Meyer, assistant professor of biology, along with graduate student Sarah Ohlemacher of the School of Science at Indiana University-Purdue University Indianapolis, have successfully demonstrated the ability to turn stem cells into retinal ganglion cells (RGCs), the neurons that conduct visual information from the eye to the brain.

21 Mar 2016

Researchers report outcomes of dipyridamole drug in treating pterygium and related dry-eye symptoms

At the Israeli Society for Vision and Eye Research conference on March 10, the MedInsight Research Institute and Center for Drug Repurposing at Ariel University presented the latest findings on positive user-reported outcomes of the repurposed drug dipyridamole in treating pterygium and related dry-eye symptoms.

15 Mar 2016

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe.

15 Mar 2016

FDA allows marketing of one-time use contact lens to help measure patient's intraocular pressure

The U.S. Food and Drug Administration today allowed marketing of a one-time use contact lens that may help practitioners identify the best time of day to measure a patient's intraocular pressure (IOP). Elevated IOP is often associated with the optic nerve damage that is characteristic of glaucoma.

7 Mar 2016

IRIDEX reports revenues of $12.1 million for fourth quarter 2015

IRIDEX Corporation today reported financial results for the fourth quarter and year ended January 2, 2016.

4 Mar 2016

Black, white Americans cope with pain differently

Researchers led by Adam T. Hirsh of the School of Science at Indiana University-Purdue University Indianapolis report that black and white Americans cope with pain differently and that blacks employ pain coping strategies more frequently than whites. The IUPUI review and analysis of 19 studies is the first to examine the entire published literature and quantify the relationship between race and the use of pain-coping strategies.

23 Feb 2016

Study reveals another clue to workings of trachoma

Another clue to the workings of trachoma - the world's leading infectious cause of blindness - has been revealed in a new study published in BMC Infectious Diseases. Researchers identified markers of genetic regulation present in the early stages of infection that could predispose children to developing the condition in its long-term, severe form.

17 Feb 2016

IRIDEX's Cyclo G6 laser system receives CE Mark approval for treatment of glaucoma

IRIDEX Corporation, a leading global provider of innovative laser systems, delivery devices and consumables in ophthalmology, today announced that it has received its CE Mark to commercialize across Europe its first laser system in its class designed solely for use in treating glaucoma and its symptoms.

16 Feb 2016

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Shire plc today announced it has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration for its investigational candidate, lifitegrast, for the treatment of signs and symptoms of dry eye disease in adults. Shire resubmitted the NDA in response to the complete response letter (CRL) the company received from the FDA on October 16, 2015.

25 Jan 2016

Incidence of childhood myopia has more than doubled over last 50 years among American children

The largest study of childhood eye diseases ever undertaken in the U.S. confirms that the incidence of childhood myopia among American children has more than doubled over the last 50 years. The findings echo a troubling trend among adults and children in Asia, where 90 percent or more of the population have been diagnosed with myopia, up from 10 to 20 percent 60 years ago.

21 Jan 2016

Age-related macular degeneration: an interview with Cathy Yelf, Macular Society

Age-related macular degeneration is a condition of the macula, a tiny area of the retina at the back of the eye. Your macula is only about the size of the grain of rice, that’s about four millimeters across.

19 Jan 2016

Three new genetic associations identified for primary open angle glaucoma

Researchers from Massachusetts Eye and Ear/Harvard Medical School and Case Western Reserve University School of Medicine have led an international effort to identify three genetic associations that influence susceptibility to primary open angle glaucoma -- the most common form of adult onset glaucoma and the leading cause of irreversible blindness in the world.

12 Jan 2016

NIH-funded analysis identifies three genes that contribute to most common form of glaucoma

An analysis funded by the National Eye Institute (NEI), part of the National Institutes of Health, has identified three genes that contribute to the most common type of glaucoma. The study increases the total number of such genes to 15.

12 Jan 2016

Head-down yoga positions fatal for glaucoma patients

Glaucoma patients may experience increased eye pressure as the result of performing several different head-down positions while practicing yoga, according to a new study published by researchers at New York Eye and Ear Infirmary of Mount Sinai in the journal PLOS ONE.

11 Jan 2016

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health grant under the Small Business Innovation Research (SBIR) Program.

22 Dec 2015

Bio Light's IOPtiMate system approved in Canada for treatment of glaucoma

Bio Light Israeli Life Sciences Investments Ltd., an emerging global ophthalmic company focused on the discovery, development and commercialization of products and product candidates which address ophthalmic conditions, announced today that its IOPtiMate system for the treatment of glaucoma has been approved by the Canadian Medical Devices Bureau, allowing the Company to commercialize the surgical system in Canada.

21 Dec 2015

BioLight announces first sale of IOPtiMate system in Portugal

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate system to a medical center located in Portugal.

8 Dec 2015

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) - the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini - as an orphan drug for the treatment of neurotrophic keratitis.

8 Dec 2015

Glaucoma News and Research

Latest Glaucoma News and Research

Liu Laboratory at Augusta University studies exosomes using Particle Metrix’s ZetaView

New technologies go far beyond traditional use of contact lenses for vision correction

IUPUI investigators use stem cells to identify potential therapies to prevent glaucoma

Researchers report outcomes of dipyridamole drug in treating pterygium and related dry-eye symptoms

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

FDA allows marketing of one-time use contact lens to help measure patient's intraocular pressure

IRIDEX reports revenues of $12.1 million for fourth quarter 2015

Black, white Americans cope with pain differently

Study reveals another clue to workings of trachoma

IRIDEX's Cyclo G6 laser system receives CE Mark approval for treatment of glaucoma

Shire announces resubmission of lifitegrast NDA to FDA for treatment of dry eye disease in adults

Incidence of childhood myopia has more than doubled over last 50 years among American children

Age-related macular degeneration: an interview with Cathy Yelf, Macular Society

Three new genetic associations identified for primary open angle glaucoma

NIH-funded analysis identifies three genes that contribute to most common form of glaucoma

Head-down yoga positions fatal for glaucoma patients

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Bio Light's IOPtiMate system approved in Canada for treatment of glaucoma

BioLight announces first sale of IOPtiMate system in Portugal

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Glaucoma News and Research

Latest Glaucoma News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in